Centessa Pharmaceuticals plc
CNTA
$16.43
-$0.57-3.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -46.41% | -61.72% | -56.04% | -2.44% | 8.86% |
| Total Depreciation and Amortization | -7.38% | 21.83% | 109.03% | 170.49% | 244.04% |
| Total Amortization of Deferred Charges | 203.72% | 35.27% | -41.20% | -16.29% | 45.10% |
| Total Other Non-Cash Items | 105.82% | 615.61% | 705.61% | 597.68% | 336.09% |
| Change in Net Operating Assets | 175.42% | 67.41% | 217.71% | 77.95% | -27.95% |
| Cash from Operations | 1.65% | -8.16% | 11.40% | 27.95% | 19.85% |
| Capital Expenditure | -125.35% | 58.02% | 79.88% | 92.18% | 90.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2,245.55% | -772.40% | 124.68% | 88.98% | 94.78% |
| Cash from Investing | -2,227.34% | -769.59% | 124.62% | 89.00% | 94.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 87.47% | 1,064.86% | 1,656.08% | 2,405.09% | 42,876.00% |
| Repurchase of Common Stock | -62.62% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 85.26% | 1,030.48% | 1,627.29% | 2,379.96% | 42,026.46% |
| Foreign Exchange rate Adjustments | -171.35% | -261.08% | 99.51% | -225.42% | -115.64% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -365.77% | 90.79% | 196.08% | 181.78% | 94.73% |